Blocking IL-1 to prevent heart failure after heart attacks
Prevention of heart failure with IL-1 blockade: a mechanistic study
['FUNDING_R01'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-11056020
This study is looking at whether a medication called anakinra, which blocks a protein that causes inflammation, can help prevent heart failure in people who have had a serious heart attack, and we're excited to see how it might improve heart health for those at risk.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-11056020 on ClinicalTrials.gov |
What this research studies
This research investigates how blocking the inflammatory protein IL-1 can help prevent heart failure in patients who have experienced a severe heart attack known as STEMI. The study will use a medication called anakinra, which inhibits IL-1, to see if it can reduce inflammation and improve heart function. By understanding the mechanisms behind this treatment, the researchers aim to provide new insights into preventing heart failure in at-risk patients. Participants will be monitored for changes in heart function and overall health over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently suffered an ST-segment elevation myocardial infarction (STEMI).
Not a fit: Patients who have not experienced a heart attack or those with chronic heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the risk of heart failure in patients recovering from heart attacks.
How similar studies have performed: Previous studies have shown promising results with IL-1 blockade in reducing heart failure risk, indicating that this approach has potential based on earlier findings.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VAN TASSELL, BENJAMIN W — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: VAN TASSELL, BENJAMIN W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.